Our results suggest that high baseline plasma FGF23 levels in end-stage renal disease patients on chronic hemodialysis are associated with an increased risk for SARS-CoV-2 infection and severe COVID-19, including hospitalization and death. Here, FGF23 is linked to stage 5 chronic kidney disease.